title: Monitoring of Risedronate by biochemical bone markers in clinical practice.
abstract: The study of trend of Risedronate 10 mg/day in menopausal women with a high level of resorptive bone marker (Betacrosslaps, CTx) by the following bone markers:Bone alkaline phosphatase (formation marker) total alkaline phosphatase (TAlP), NMID osteocalcin, undercarboxylated osteocalcin (UcOC) and procollagen type 1 carboxyl propeptides (PICP). Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal. The level of undercarboxylated osteocalcin was increased after one year of treatment; it may be a sign of vitamin K2 deficiency. The bone alkaline phosphatase was decreased at the end of 12 months and Procollagen type 1 carboxyl propeptides (PICP) of twelfth month changed significantly compared to the sixth months of treatment (p=0.001) The once week 70 mg/week group also changed of CTx the same as daily dose group.
authors.affiliation: Department of Orthopaedic Surgery, Faculty of Medicine, Mahidol University, Bangkok 10700, Thailand. todrnarong@yahoo.com
authors.forename: Narong
authors.initials: N
authors.lastname: Bunyaratavej
mesh_terms: D000469:Alkaline Phosphatase / Q000187:drug effects; D015415:Biomarkers / Q000032:analysis*; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001862:Bone Resorption / Q000188:drug therapy*; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology; D016903:Drug Monitoring; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D015675:Osteocalcin / Q000187:drug effects; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010446:Peptide Fragments / Q000187:drug effects; D011347:Procollagen / Q000187:drug effects; D000068296:Risedronic Acid; D013997:Time Factors; D016896:Treatment Outcome; D014813:Vitamin K Deficiency
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D010446:Peptide Fragments; D011347:Procollagen; C042813:procollagen type I carboxy terminal peptide; D015675:Osteocalcin; D000469:Alkaline Phosphatase; D000068296:Risedronic Acid; D012968:Etidronic Acid